Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Potential Prognostic Markers for Relapsed/Refractory vs. Responsive Acute Myeloid Leukemia

1 Jun 2022

Abstract excerpt

Acute myeloid leukemia (AML) is a heterogeneous disease. A significant proportion of AML patients is refractory to clinical treatment or relapses. Our aim is to determine new potential AML clinical treatment prognosis markers. We investigated various cell fate and epigenetic regulation important gene level differences between refractory and responsive AML patient groups at diagnosis stage and after clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Epigenetics and DNA Methylation
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35681732
DOI: 10.3390/cancers14112752

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Potential Prognostic Markers for Relapsed/Refractory vs. Responsive Acute Myeloid LeukemiaPMID 35681732Read ↗

RUNX1/CEBPA Mutation in Acute Myeloid Leukemia Promotes Hypermethylation and Indicates for Demethylation Therapy.Semantic proximity Read ↗

Impact of RUNX1 mutations at distinct sites on the clinical characteristics and prognosis of patients with acute myeloid leukemia.Semantic proximity Read ↗

Acute myeloid leukemia subgroups identified by pathway-restricted gene expression signatures.Semantic proximity Read ↗

Clinical and Molecular Predictors of Response and Survival Following Venetoclax Plus Hypomethylating Agents in Relapsed/Refractory Acute Myeloid Leukemia: A Single-Center Study in Chinese PatientsSemantic proximity Read ↗

Gene Expression Profiles Associated with Pediatric Relapsed AMLSemantic proximity Read ↗

Impact of different CEBPA mutations on therapeutic outcome in acute myeloid leukemia.Semantic proximity Read ↗

Targeting histone methylation to reprogram the transcriptional state that drives survival of drug-tolerant myeloid leukemia persistersSemantic proximity Read ↗

Acute myeloid leukaemia: recent data on prognostic gene mutations, in relation to stratified therapies for elderly patients.Semantic proximity Read ↗

TET2 expression is a potential prognostic and predictive biomarker in cytogenetically normal acute myeloid leukemiaSemantic proximity Read ↗

Association of relapse-linked ARID5B single nucleotide polymorphisms with drug resistance in B-cell precursor acute lymphoblastic leukemia cell linesSemantic proximity Read ↗

Comparative Transcriptomic Analysis of ATRA-Resistant and ATRA-Sensitive APL Cell Lines Identifies lncRNA Biomarkers Associated with Drug ResistanceSemantic proximity Read ↗

Identification of the Thyrotropin-Releasing Hormone (TRH) as a Novel Biomarker in the Prognosis for Acute Myeloid Leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.